April 13, 2021-A new study shows that people who live with people with COVID-19 appear to have strong protection against infection after receiving a regenerant antibody mixture.
The results of the study show that in addition to preventing the worst results coronavirus The company said on Monday that if the infection is given as early as possible, the cocktail can also prevent people from getting sick in the first place.
“With more than 60,000 Americans continuing to be diagnosed with COVID-19 every day, the REGEN-COV antibody mixture may help provide immediate protection to unvaccinated people from the virus, and we are also working hard to understand its potential. , Can continue to provide protection for immunocompromised patients who may have a poor immune response vaccine“, Dr. George Yancopoulos, President and Chief Scientific Officer of Regeneron, said in a statement.
Regeneron said in the statement that it will require the U.S. Food and Drug Administration (FDA) to expand the emergency authorized use of the drug-for high-risk people who already have COVID-19 but have not yet been hospitalized-allowing it to be used for preventive purposes in “appropriate Population”.
Dr. Myron Cohen, a researcher at the University of North Carolina, told the New York Times that in the United States and around the world, “a very large number of people” are well suited to receive these drugs for preventive use. He leads the monoclonal antibody research of the Covid Prevention Network, a program initiated by the National Institutes of Health that helped oversee the clinical trials of Regeneron.
“Not everyone will take vaccine, No matter what we do, and not everyone will respond to the vaccine. “Cohen pointed out.
The new data for the Regeneron antibody mix comes from Clinical Trials The study recruited more than 1,500 people living in the same houses as people who tested positive for the virus in the past four days. Compared with volunteers who received Regeneron drug injections, those who received Regeneron drug injections were 81% less likely to develop COVID-19 Placebo, The company said.
Dr. Rajesh Gandhi, an infectious disease physician at Massachusetts General Hospital, was not involved in the study. He told The Times that the data is “promising” for people who have not been vaccinated. But he pointed out that the type of patient needed to determine whether to use the drug preventively in patients with weakened immune function is not within the scope of the trial. Gandhi said: “I would say we don’t know yet.”
Regeneron’s cocktail, a combination of two drugs, designed to mimic the current immune system To defend against this virus, President Donald Trump was given to him after he contracted COVID-19 last fall.
In November last year, the treatment received emergency authorization. Doctors are using it and another antibody mixture from Eli Lilly for high-risk COVID-19 patients to prevent serious illness and hospitalization.
However, many hospitals and clinics do not make treatment a priority because they are time-consuming and difficult to manage, mainly because they must be injected intravenously. As with recent research, the Regeneron plan requires the FDA to allow its drug to be administered by injection, which will allow it to be administered faster and easier.